- Home
- ACTU vs LUCD Comparison
ACTU vs LUCD Comparison
Compare ACTU & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- LUCD
- Stock Information
- Founded
- ACTU 2015
- LUCD 2018
- Country
- ACTU United States
- LUCD United States
- Employees
- ACTU N/A
- LUCD N/A
- Industry
- ACTU
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ACTU
- LUCD Health Care
- Exchange
- ACTU NYSE
- LUCD Nasdaq
- Market Cap
- ACTU 135.0M
- LUCD 135.6M
- IPO Year
- ACTU 2024
- LUCD 2021
- Fundamental
- Price
- ACTU $10.35
- LUCD $1.13
- Analyst Decision
- ACTU Strong Buy
- LUCD Strong Buy
- Analyst Count
- ACTU 1
- LUCD 4
- Target Price
- ACTU $20.00
- LUCD $3.88
- AVG Volume (30 Days)
- ACTU 71.1K
- LUCD 961.7K
- Earning Date
- ACTU 05-21-2025
- LUCD 05-14-2025
- Dividend Yield
- ACTU N/A
- LUCD N/A
- EPS Growth
- ACTU N/A
- LUCD N/A
- EPS
- ACTU N/A
- LUCD N/A
- Revenue
- ACTU N/A
- LUCD $4,346,000.00
- Revenue This Year
- ACTU N/A
- LUCD $107.75
- Revenue Next Year
- ACTU N/A
- LUCD $231.37
- P/E Ratio
- ACTU N/A
- LUCD N/A
- Revenue Growth
- ACTU N/A
- LUCD 79.00
- 52 Week Low
- ACTU $5.51
- LUCD $0.63
- 52 Week High
- ACTU $11.73
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- LUCD 36.90
- Support Level
- ACTU N/A
- LUCD $1.19
- Resistance Level
- ACTU N/A
- LUCD $1.24
- Average True Range (ATR)
- ACTU 0.00
- LUCD 0.07
- MACD
- ACTU 0.00
- LUCD -0.01
- Stochastic Oscillator
- ACTU 0.00
- LUCD 4.17
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.